Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Stopped early · Phase 1
Conditions studied: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
In brief
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer who are platinum resistant or refractory. The study will assess if this combination will optimize anti-tumor activity, block tumor growth and overcome the resistance to PARP inhibitor treatment. The study consists 2 parts. In Part 1 dose escalation, the objective is to determine the maximum toleration dose (MTD) of the combination. The final recommended phase 2 dose (RP2D) of CYH33 in combination with olaparib will be based on the totality of an overall assessment of available safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy which could be the MTD or a dose level lower in specific cohorts of patients. In Part 2 dose expansion, the main objective is to evaluate the efficacy at RP2D.
Key facts
- Study ID
- NCT04586335
- Run by
- Haihe Biopharma Co., Ltd.
- People needed
- 24
- Starts
- 2020-09-28
- Expected to finish
- 2023-02-15
- Last updated by the study team
- 2024-03-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale Cancer Center — New Haven, Connecticut, United States
- UT Southwestern: Simmons Cancer Center — Dallas, Texas, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Scientia Cancer Centre — Sydney, New South Wales, Australia
- Integrated Oncology Network PTY LTD — Brisbane, Queensland, Australia
- Monash Cancer Centre — Melbourne, Victoria, Australia
- Fudan University - Pudong Medical Center — Shanghai, Shanghai Municipality, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.